Stockreport

Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update

Rani Therapeutics Holdings, Inc. - Class A  (RANI) 
PDF - Announced partnership with ProGen on development of RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity - - Phase 1 study for RT-114 expected to ini [Read more]